Earnings NYSE Nasdaq 100 U.S. Tech Politics Science AI SEC Business Wall Street Energy Dow Jones Dividend Bitcoin (BTC) Markets NVIDIA (NVDA) Investing Economy S&P 500 China Donald Trump Fed World Crude Oil Tesla (TSLA) Inflation Money Gold Software Apple (AAPL) U.K. Wealth Entertainment Health Amazon (AMZN) Retail 3M (MMM) Real Estate Taxes Europe Natural Gas Elon Musk Microsoft (MSFT) Security Meta Platforms (META) Retirement Truist Financial Corp (TFC) Canada Current Boeing (BA) Options Jim Cramer Hedge Funds Insurance Tax Sports Live Google Economics Manufacturing Pharmaceuticals Cars Mining Costco (COST) Airlines Warren Buffett War Japan Silver Construction Interest Rates York Ukraine BlackRock (BLK) New York Holidays Kamala Harris Finance Goldman Sachs (GS) REITs Space Mortgage KeyCorp (KEY) Internet Walmart (WMT) Aerospace JPMorgan (JPM) Ethereum (ETH) Intel (INTC) Walt Disney (DIS) Enterprise OpenAI ChatGPT GBP USD Netflix (NFLX) Australia Boston Morgan Stanley (MS) IndiaMore +
Market Insider Market Insider
  • Stocks
  • ETFs
  • Bonds
  • Commodities
  • Earnings
  • Dividends
  • REITs
  • IPOs
  • Cryptocurrency
  • Forex
  • Tech
  • Politics
  • +

3 days FDA Accepts SNY and REGN’s Dupixent Re-Submitted sBLA for UrticariaZacks

The FDA is set to give its decision on SNY and REGN’s sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Regeneron Pharma (REGN)

X       

2 days Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)Seeking Alpha X       

2 days Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3Insider Monkey X       

1 week 2 Top Growth Stocks to Buy on the DipThe Motley Fool X       

3 weeks Regeneron Pharma earnings beat by $0.74, revenue topped estimatesInvesting.com X       

3 weeks Regeneron to Report Q3 Earnings: What’s in the Offing?Zacks X       

4 weeks Brighton Jones LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)MarketBeat X       

4 weeks Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Silver Oak Securities IncorporatedMarketBeat X       

4 weeks Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Neutral” Rating from Cantor FitzgeraldMarketBeat X       

4 weeks Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,080.00 at BarclaysMarketBeat X       

4 weeks Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,050.00 by Analysts at Wells Fargo & CompanyMarketBeat X       

4 weeks Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of CanadaMarketBeat X       

1 month Creative Planning Purchases 2,178 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)MarketBeat X       

1 month Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Raymond James & AssociatesMarketBeat X       

More news +
Home | Contact
  • X

© 2024 Market Insider